87 related articles for article (PubMed ID: 1705081)
1. Iloprost, a stable analogue of PGI2: clinical results and pathophysiological considerations.
Stock G; Müller B; Krais T; Schillinger E
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():583-9. PubMed ID: 1705081
[No Abstract] [Full Text] [Related]
2. [Microcirculation in peripheral arterial occlusive diseases will improve. Prostaglandin can prevent surgery].
MMW Fortschr Med; 2003 Dec; 145(51-52):41. PubMed ID: 14974333
[No Abstract] [Full Text] [Related]
3. Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease.
Müller B; Krais T; Stürzebecher S; Witt W; Schillinger E; Baldus B
Biomed Biochim Acta; 1988; 47(10-11):S40-4. PubMed ID: 2470358
[TBL] [Abstract][Full Text] [Related]
4. The effects of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischaemia.
Mazzone A; Cusa C; Bucci L; Vezzoli M; Ghio S; Buggia I; Regazzi MB; Fossati G; Mazzucchelli I; Gritti D
Eur J Clin Invest; 1999 Jan; 29(1):1-5. PubMed ID: 10092981
[TBL] [Abstract][Full Text] [Related]
5. Clinical benefits of iloprost, a stable prostacyclin (PGI2) analog, in severe peripheral arterial disease (PAD).
Oberender H; Krais T; Schäfer M; Belcher G
Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():311-6. PubMed ID: 2473610
[No Abstract] [Full Text] [Related]
6. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.
Arosio E; Sardina M; Prior M; De Marchi S; Zannoni M; Bianchini C
Eur Rev Med Pharmacol Sci; 1998; 2(2):53-9. PubMed ID: 10229559
[TBL] [Abstract][Full Text] [Related]
7. Iloprost, stable analogue of the prostacyclin, is able to improve the tissue resistance to ischaemia.
Andreozzi GM; Di Pino L; Li Pira M; Butto G; Martini R; Signorelli S
Int Angiol; 1994 Mar; 13(1):68-9. PubMed ID: 7521383
[TBL] [Abstract][Full Text] [Related]
8. Experimental animal models of arterial thrombosis and the screening of platelet-inhibiting, anti-thrombotic drugs: a review.
Philp RB
Methods Find Exp Clin Pharmacol; 1979 Oct; 1(4):197-224. PubMed ID: 399655
[No Abstract] [Full Text] [Related]
9. Intravenous infusion of iloprost in arterial occlusive disease: dose-dependent effects on skin microcirculation.
Caspary L; Creutzig A; Alexander K
Eur J Clin Pharmacol; 1991; 41(2):131-6. PubMed ID: 1720738
[TBL] [Abstract][Full Text] [Related]
10. Augmented platelet-endothelial adhesion induced by PGI2 receptor desensitization.
Darius H; Binz C; Veit K; Fisch A
Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():427-9. PubMed ID: 7537435
[No Abstract] [Full Text] [Related]
11. Interaction between NO donors and iloprost in human vascular smooth muscle, platelets, and leukocytes.
Gryglewski RJ; Korbut R; Trabka-Janik E; Zembowicz A; Trybulec M
J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S124-8. PubMed ID: 2484690
[TBL] [Abstract][Full Text] [Related]
12. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost.
Balzer K; Bechara G; Bisler H; Clevert HD; Diehm C; Heisig G; Held K; Mahfoud Y; Mörl H; Rücker G
Int Angiol; 1991; 10(4):229-32. PubMed ID: 1724669
[TBL] [Abstract][Full Text] [Related]
13. Cocaine-related peripheral vascular occlusive disease treated with iloprost in addition to anticoagulants and antibiotics.
Mazzone A; Giani L; Faggioli P; Pichini S; Pacifici R
Clin Toxicol (Phila); 2007; 45(1):65-6. PubMed ID: 17357385
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacologic concepts for clinical use of prostaglandin E1].
Schrör K
Vasa Suppl; 1991; 33():335-6. PubMed ID: 1788746
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model.
Ferrara DE; Liu X; Espinola RG; Meroni PL; Abukhalaf I; Harris EN; Pierangeli SS
Arthritis Rheum; 2003 Nov; 48(11):3272-9. PubMed ID: 14613293
[TBL] [Abstract][Full Text] [Related]
16. Endothelium as a therapeutical target in peripheral occlusive arterial diseases: consideration for pharmacological interventions.
Cirillo R; Aliev G; Hornby EJ; Prosdocimi M
Pharmacol Res; 1994; 29(4):293-311. PubMed ID: 7971683
[TBL] [Abstract][Full Text] [Related]
17. Combined administration of nitric oxide gas and iloprost during cardiopulmonary bypass reduces platelet dysfunction: a pilot clinical study.
Chung A; Wildhirt SM; Wang S; Koshal A; Radomski MW
J Thorac Cardiovasc Surg; 2005 Apr; 129(4):782-90. PubMed ID: 15821644
[TBL] [Abstract][Full Text] [Related]
18. Mode of action of PGI2 and of its stable derivative iloprost on platelets and leukocytes.
Tremoli E; Colli S; Paoletti R
Thromb Res Suppl; 1990; 11():33-42. PubMed ID: 1703669
[No Abstract] [Full Text] [Related]
19. [Experimental platelet aggregation and arterial thrombosis. Effect of aspirin].
Bousser MG; Lecrubier C
Nouv Presse Med; 1973 Jun; 2(25):1687-92. PubMed ID: 4718537
[No Abstract] [Full Text] [Related]
20. The effect of flavonoids on blood-vessel wall interactions.
Beretz A; Cazenave JP
Prog Clin Biol Res; 1988; 280():187-200. PubMed ID: 3051026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
